Corneal Ectasia

Ophthalmology
1
Pipeline Programs
2
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Glaukos
GlaukosALISO VIEJO, CA
2 programs
1
riboflavin: 0.12% riboflavin ophthalmic solution with the KXL systemPhase 31 trial
Corneal Collagen Cross-linkingN/A1 trial
Active Trials
NCT03319082UnknownEst. Feb 2026
NCT01643252Withdrawn
Azalea Therapeutics
Azalea TherapeuticsCA - Berkeley
1 program
Ocular Topography and Wavefront AberrometryN/A1 trial
Active Trials
NCT06859398Completed52Est. Nov 2025

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Glaukosriboflavin: 0.12% riboflavin ophthalmic solution with the KXL system
Azalea TherapeuticsOcular Topography and Wavefront Aberrometry
GlaukosCorneal Collagen Cross-linking

Clinical Trials (3)

Total enrollment: 52 patients across 3 trials

NCT01643252Glaukosriboflavin: 0.12% riboflavin ophthalmic solution with the KXL system

Safety and Efficacy Study for Corneal Collagen Cross-Linking in Eyes With Corneal Ectasia After Refractive Surgery

Start: Jul 2012
Phase 3Withdrawn
NCT06859398Azalea TherapeuticsOcular Topography and Wavefront Aberrometry

KeratoConus Data Acquisition With Topography and Aberrometry

Start: Jun 2025Est. completion: Nov 202552 patients
N/ACompleted
NCT03319082GlaukosCorneal Collagen Cross-linking

Observational Registry to Assess the Durability of Effect of CXL in Patients With Corneal Ectasia After Refractive Surgery

Start: Oct 2017Est. completion: Feb 2026
N/AUnknown

Related Jobs in Ophthalmology

Lead Data Manager

Genomics
Remote
8h ago

Cleanroom and Laboratory Technician

SAB BIO
8h ago

APAC Regulatory Affairs Manager

Johnson & Johnson
Singapore, Singapore
Yesterday

Clinical Operations Manager

Johnson & Johnson
Irvine, California, United States of America
Yesterday
$117K - $201K/yr

Site Delivery Leader MLL

Johnson & Johnson
Gent, East Flanders, Belgium
Yesterday

BM 喀什 PSR HY

Johnson & Johnson
Urumqi, Xinjiang, China
Yesterday

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
2 companies competing in this space

Related Indications

Myopia(127)Cataract(116)Open-Angle Glaucoma(102)Glaucoma(92)Dry Eye(74)Age-Related Macular Degeneration(73)Dry Eye Disease(43)Neovascular Age-related Macular Degeneration(40)Macular Degeneration(37)Diabetic Retinopathy(25)